Tempest Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund report a 9.9% beneficial ownership stake in Tempest Therapeutics, Inc.